Exela Pharma Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Exela Pharma Sciences is a private, revenue-generating company specializing in sterile injectables, with a dual business model of proprietary product development and contract manufacturing. Headquartered in Lenoir, North Carolina, it leverages significant cGMP manufacturing capacity across various delivery formats, including vials, IV bags, and pre-filled syringes. The company has established itself as a reliable domestic manufacturer, creating jobs in a rural area and receiving industry awards for supply chain and manufacturing excellence. Its commercial-stage operations are focused on bringing high-quality, affordable medicines to market efficiently.

Drug DeliverySmall Molecules

Technology Platform

Advanced cGMP sterile manufacturing infrastructure for liquid vials, IV bags, lyophilized vials, and pre-filled syringes, governed by a Quality by Design (QbD) philosophy.

Opportunities

Strong demand for reliable, domestic sterile injectable manufacturing capacity driven by drug shortages and supply chain resilience initiatives.

Growth in the biologics and injectables pipeline expands the addressable market for its CDMO services.

Continued need for affordable generic medicines supports its proprietary product business.

Risk Factors

Intense competition from larger generic drug makers and CDMOs.

High regulatory risk associated with sterile manufacturing; an FDA compliance failure could be catastrophic.

Pricing pressures in the generic drug market and potential client concentration in the CDMO business.

Competitive Landscape

Exela competes in the fragmented but competitive sterile injectables CDMO and generic manufacturing market. Key competitors include large CDMOs like Catalent, Baxter (BioPharma Solutions), and Pfizer CentreOne, as well as numerous generic sterile injectable manufacturers such as Fresenius Kabi, Hikma, and Hospira (Pfizer). Its differentiation lies in its integrated model, US-based capacity, multi-format capabilities, and focus on quality and service.

More companies in Small Molecule Drugs →More companies in United States →